Error message

Deprecated function: Function create_function() is deprecated in eval() (line 1 of /home/dignumltd/domains/ : eval()'d code).

Cofinimmo appoints CEO

Contributor: Editorial, 8 February 2018

Office and healthcare property investor Cofinimmo announced it had co-opted Mr Jean-Pierre Hanin as Director of the group to succeed Mr Jean-Edouard Carbonnelle whose term as Managing Director expires at the next Ordinary General Meeting.

Ablynx Board changes

Contributor: Editorial, 8 January 2018

Biopharmaceutical company Ablynx announced that Dr Peter Fellner, who has served as Chairman since 2013, has decided to resign from the Board, with immediate effect, and will be succeeded by Dr Bo Jesper Hansen who has been a Non-executive Director of Ablynx since November 2013.

Ablynx reports Q3 2017

Contributor: Editorial, 16 November 2017

Biopharmaceutical company Ablynx reported revenue was lower in the first nine months of 2017 at €44.7 million, due to lower upfront payments, compared to €68.9 million in the same period of 2016.

Ablynx prices US IPO

Contributor: Editorial, 25 October 2017

Biopharmaceutical company Ablynx announced it had priced its US initial public offering of 11,430,000 ordinary shares in the form of American Depositary Shares at US$17.50 per ADS, totalling US$200 million.

Ablynx proposed global offering

Contributor: Editorial, 3 October 2017

Biopharmaceutical company Ablynx announced it had filed a registration statement with the US Securities and Exchange Commission for a proposed global offering of its ordinary shares, including American Depositary Shares in the US and ordinary shares in a concurrent private placement in Europe and countries outside of the US and Canada.